CHALFONT ST. GILES, UK, 11 January 2018 – GE Healthcare announced today the approval in Canada of DaTscan™ (Ioflupane I 123 Injection), the first Health Canada approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with a suspected parkinsonian syndrome (PS) such as
https://www.genewsroom.com/press-releases/first-imaging-agent-its-kind-now-approved-canada-help-physicians-diagnosis-patients